By: Maribel Yoo On: June 20, 2018 In: Nexus Strategy, Portfolio Comments: 0
WindMIL Logo

WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs™) for cancer immunotherapy.

As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to extract, activate and expand these cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxicity, and long persistence.

Deal Source

Dr. Drew Pardoll

Board Representation

George Petrocheilos